Included in the formulation
АТХ:J.06.B.B.30 Immunoglobulins specific in combinations
Pharmacodynamics:
Selectively blocks histamine H1-receptors, reduces the permeability of capillaries, inhibits the processes of exudation and formation of edema, removes the phenomenon of itching. It blocks cholinergic receptors in the central nervous system and peripheral tissues, shows local anesthetic activity, does not have sedative effect.
Inhibits IgE-mediated reactivity of basophils. Prevents release of histamine from mast cells, suppressing their degranulation.
Pharmacokinetics:
After subcutaneous or intramuscular injection, the bioavailability of the drug is 100%. The maximum concentration in the blood plasma is maintained for 21 days.
Penetrates through the blood-brain and placental barriers, enters the breast milk.
The half-life period is 21 days; in patients with primary hypogammaglobulinemia (agammaglobulinemia), the half-life period is 32 days.
Indications:
It is used to treat allergic diseases of the respiratory tract (bronchial asthma, allergic rhinitis, hay fever), skin (hives, eczema, allergic dermatitis).Used for neurological disorders of allergic genesis (neurodermatitis, migraine), premenstrual tension syndrome.
VI.G40-G47.G43 Migraine
X.J30-J39.J30 Vasomotor and allergic rhinitis
X.J30-J39.J31 Chronic rhinitis, nasopharyngitis and pharyngitis
X.J40-J47.J45 Asthma
XII.L20-L30.L30.9 Dermatitis, unspecified
XII.L20-L30.L20 Atopic dermatitis
XII.L50-L54.L50 Hives
XIV.N80-N98.N94.3 Premenstrual tension syndrome
Contraindications:
Children under 6 years old, acute or chronic infectious diseases in the acute stage, pregnancy and lactation, individual intolerance.
Carefully:
Hypersensitivity.
Pregnancy and lactation:
Recommendations for FDA - Category C. Contraindicated in pregnancy and lactation.
Dosing and Administration:Use in children
From the age of 6: intramuscularly or subcutaneously, 1.0 ml every 2-3 days, with a course of up to 6-9 injections. Re-introduction after one month in the number of 3 injections with an interval of 2-3 days. Subsequent administration takes place after 3 or 6 months.
Adults
Intramuscularly or subcutaneously, 2.0 ml every 2-3 days, with a course of up to 6-9 injections. Re-introduction after one month in the number of 3 injections with an interval of 2-3 days. Subsequent administration takes place after 3 or 6 months.
The highest daily dose: 2.0 ml.
The highest single dose: 2.0 ml.
Side effects:
Central and peripheral nervous system: headache, dizziness, rarely - hallucinations.
The cardiovascular system: tachycardia, arterial hypotension, cyanosis, dyspnea, chest pain, tides, chills.
Digestive system: abdominal pain, diarrhea.
Musculoskeletal system: myalgia.
Dermatological reactions: Hyperhidrosis.
Allergic reactions.
Overdose:
Cases of overdose are not described.
Treatment is symptomatic.
Interaction:
Clinically significant interactions are not described.
Special instructions:
After the introduction of immunoglobulin, a passive increase in the antibody content in the patient's blood is noted, which can lead to erroneous false positive interpretation of the results of serological testing.